Harrow (HROW) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
199.6M
Gross Profit
150.4M
75.33%
Operating Income
9.1M
4.55%
Net Income
-17.5M
-8.76%
EPS (Diluted)
-$0.49
Balance Sheet Metrics
Total Assets
389.0M
Total Liabilities
319.7M
Shareholders Equity
69.3M
Debt to Equity
4.61
Cash Flow Metrics
Operating Cash Flow
-23.7M
Free Cash Flow
-60.9M
Revenue & Profitability Trend
Harrow Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 199.6M | 130.2M | 88.6M | 72.5M | 48.9M |
| Cost of Goods Sold | 49.2M | 39.6M | 25.4M | 18.2M | 14.5M |
| Gross Profit | 150.4M | 90.6M | 63.2M | 54.3M | 34.4M |
| Operating Expenses | 141.3M | 89.7M | 61.3M | 52.4M | 33.7M |
| Operating Income | 9.1M | 811.0K | 1.9M | 1.9M | 748.0K |
| Pre-tax Income | -17.3M | -23.7M | -14.0M | -17.9M | -3.4M |
| Income Tax | 161.0K | 701.0K | 75.0K | 133.0K | 4.0K |
| Net Income | -17.5M | -24.4M | -14.1M | -18.0M | -3.4M |
| EPS (Diluted) | -$0.49 | -$0.75 | -$0.51 | -$0.69 | -$0.13 |
Income Statement Trend
Harrow Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 189.7M | 139.5M | 118.3M | 60.7M | 41.0M |
| Non-Current Assets | 199.3M | 172.7M | 39.1M | 37.7M | 16.5M |
| Total Assets | 389.0M | 312.2M | 157.4M | 98.3M | 57.5M |
| Liabilities | |||||
| Current Liabilities | 91.3M | 49.3M | 18.6M | 9.7M | 10.8M |
| Non-Current Liabilities | 228.3M | 192.4M | 111.5M | 77.7M | 19.8M |
| Total Liabilities | 319.7M | 241.8M | 130.1M | 87.4M | 30.6M |
| Equity | |||||
| Total Shareholders Equity | 69.3M | 70.4M | 27.2M | 10.9M | 26.8M |
Balance Sheet Composition
Harrow Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -17.5M | -24.4M | -14.1M | -18.0M | -3.4M |
| Operating Cash Flow | -23.7M | 4.8M | -4.8M | -9.6M | -3.2M |
| Investing Activities | |||||
| Capital Expenditures | -1.6M | -1.5M | -2.6M | -1.8M | -862.0K |
| Investing Cash Flow | 3.9M | -1.5M | 3.4M | 17.9M | -849.0K |
| Financing Activities | |||||
| Dividends Paid | - | - | 0 | -127.0K | - |
| Financing Cash Flow | 27.4M | 126.1M | 53.5M | 51.4M | 1.4M |
| Free Cash Flow | -60.9M | -148.7M | -6.1M | -23.4M | -2.1M |
Cash Flow Trend
Harrow Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-64.78
Forward P/E
30.10
Price to Book
19.58
Price to Sales
5.34
PEG Ratio
30.10
Profitability Ratios
Profit Margin
-10.19%
Operating Margin
-23.48%
Return on Equity
-37.31%
Return on Assets
0.90%
Financial Health
Current Ratio
0.91
Debt to Equity
410.02
Beta
0.40
Per Share Data
EPS (TTM)
-$0.61
Book Value per Share
$1.58
Revenue per Share
$5.96
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| hrow | 1.1B | -64.78 | 19.58 | -37.31% | -10.19% | 410.02 |
| Zoetis | 70.3B | 28.34 | 15.12 | 52.09% | 27.12% | 145.63 |
| Haleon Plc - ADR | 47.2B | 25.01 | 5.88 | 8.95% | 12.84% | 63.41 |
| Supernus | 1.8B | 28.53 | 1.72 | 6.32% | 9.27% | 3.13 |
| Indivior PLC | 1.7B | 530.50 | -6.04 | -0.57% | -5.30% | -1.29 |
| Bausch Health | 2.3B | -47.00 | -9.23 | 14.29% | -0.41% | -89.63 |
Financial data is updated regularly. All figures are in the company's reporting currency.